How much does ERA testing cost for IVF in China? ERA test price and scope analysis

Opening: Real consultation scenario

Clinic Dialogue — A 41-year-old woman, who had two embryo transfers without implantation, came with a thick stack of test reports and asked: "Doctor, all my tests are normal, my endometrial thickness is good, so why didn't it implant? Should I do ERA? How much does ERA testing actually cost?"

Module I: Actual Process

Actual Process of ERA Testing

ERA (Endometrial Receptivity Analysis) determines whether the endometrium is in the "receptive phase"—the window of implantation most suitable for embryo implantation—by analyzing the gene expression profile of endometrial tissue at a specific time point. The specific procedure is as follows:

1. Simulated or natural cycle preparation: The doctor chooses a hormone replacement therapy (HRT) or natural cycle based on the patient's condition, monitoring endometrial thickness and morphology starting from day 5 to 7 after medication.
2. Endometrial biopsy sampling: At the same time point as the planned transfer (usually day 5 to 7 after progesterone conversion), a small amount of endometrial tissue is gently scraped using a disposable endometrial sampling curette or catheter under ultrasound guidance. The entire process takes about 2-3 minutes, requires no anesthesia, and normal activities can be resumed afterward.
3. Sample submission: The specimen is placed in a special preservation solution and transported to the testing laboratory via cold chain. Major domestic testing platforms include Igenomix (Spain), BGI's NGS platform, and some self-built platforms in reproductive centers.
4. Report interpretation and transfer timing adjustment: The report is issued in about 2-4 weeks. Results are categorized as "receptive phase," "pre-receptive phase," or "post-receptive phase." If a window shift is indicated, the doctor will adjust the number of days of progesterone use accordingly and reschedule the transfer timing.

Module A: Direct Answer

How much does ERA testing cost for IVF in China?

For ERA testing conducted at正规 reproductive centers in China, the single-test cost ranges from 3500 to 7500 RMB, with most concentrated between 4000 and 6000 RMB. The specific price is influenced by the following factors:

• Testing platform: The Igenomix platform is generally more expensive (approximately 5500-7500 RMB), while domestic NGS platforms are relatively cheaper (approximately 3500-5000 RMB).
• Hospital level and region: Pricing at tertiary hospital reproductive centers in first-tier cities is generally higher than in second-tier cities, but the difference does not exceed 1500 RMB.
• Whether biopsy surgery fees are included: Some hospitals quote "ERA testing fees" that only cover laboratory analysis, and an additional 300-800 RMB for endometrial biopsy operation and ultrasound monitoring fees may be charged. Confirm the cost breakdown before signing the contract.

Overall, the total cost for one complete ERA test (biopsy + submission + report interpretation) mostly falls within the 4000 to 8000 RMB range. It is not covered by medical insurance and must be paid out-of-pocket.

Module K: Cost Influencing Factors

Detailed Explanation of Cost Influencing Factors

Factor	Impact Range	Explanation
Testing platform	±2000 RMB	Imported platforms (Igenomix) have higher costs; domestic platforms (BGI, Berry, etc.) are cheaper, with no significant difference in result accuracy.
Hospital pricing strategy	±1000 RMB	Some reproductive centers price ERA as a "special feature" higher, but most hospitals price based on cost.
Biopsy surgery and anesthesia	+500～1200 RMB	If painless anesthesia (intravenous sedation) is used, the cost increases; routine sampling does not require anesthesia.
Repeat testing	Full additional cost	If the first sampling fails or the result is inconclusive, a new biopsy and payment are required.

Module G: Most Easily Overlooked Details

3 Most Easily Overlooked Details

• Biopsy timing must be precise: The value of ERA testing is entirely based on "sampling at the correct simulated time point." If the endometrial preparation protocol is inconsistent with the actual transfer cycle, the test results may be distorted. Ensure the conversion day and medication protocol are exactly the same as the simulated cycle with your doctor.
• One ERA only reflects one time point: The ERA report only indicates "whether the endometrium is in the receptive phase at the time point of this biopsy." It cannot infer conditions at other time points, nor can it replace re-evaluation in subsequent cycles.
• Some hospitals outsource sample submission: Some reproductive centers send samples to third-party laboratories, which may increase report waiting time (up to 5 weeks) and communication costs. Choose centers with their own testing platform or long-term cooperative laboratories.

Module H: Most Common Pitfalls

3 Most Common Misconceptions

• "Doing ERA guarantees implantation" — ERA only addresses the problem of "window shift." Embryo chromosomal abnormalities, endometrial polyps, endometritis, immune factors, etc., can also cause failure. ERA cannot replace hysteroscopy, embryo PGT-A screening, and immune evaluation.
• "Everyone with recurrent failure should do ERA" — If uterine cavity pathologies (adhesions, polyps, endometritis) or chromosomal abnormalities in the couple have never been ruled out, addressing these causes first is more cost-effective. ERA is suitable for those who "still have recurrent implantation failure after excluding known causes."
• "Choose whichever platform is cheaper" — The stability of test results is more important than price. Different platforms have different reference databases and algorithms. Prioritize platforms with sufficient clinical validation data and cooperative experience with your reproductive center.

Module C: Doctor's Perspective

Reproductive Doctors' Real Views on ERA

In clinical practice, ERA is regarded as a "precision diagnostic tool" but not a first-line routine test. Our center holds the following attitude towards ERA:

• Clear indications: Mainly recommended for patients with ≥2 failed transfers of good-quality embryos, after excluding endometrial lesions, chromosomal abnormalities, and immune issues.
• Not recommended for first transfer: For first-time transfer patients, the incidence of window shift is only about 10%–15%, making routine ERA use not cost-effective.
• Result interpretation requires experience: When the report shows "pre-receptive phase" or "post-receptive phase," the adjustment of progesterone dosage (advancing or delaying by 1 day/2 days) needs to be combined with the patient's past cycle characteristics; there is no uniform formula.

Module B: Why Does This Problem Occur

Why Does Window Shift Occur?

Endometrial receptivity is influenced by estradiol, progesterone concentrations, and the local gene regulatory network of the endometrium. The following groups are more prone to window shift:

• Age ≥38 years: Ovarian function decline leads to fluctuations in estrogen levels, potentially altering the endometrium's response to progesterone.
• Thin endometrium or history of multiple uterine operations: After damage to the basal layer of the endometrium, the gene expression profile during regeneration and repair may shift.
• Unexplained infertility: Some patients have congenital variations in endometrial gene expression, resulting in a naturally shorter or shifted window.
• Polycystic ovary syndrome (PCOS): Chronic anovulation or luteal phase deficiency exposes the endometrium to an abnormal hormonal environment.

Module Q: Frequently Asked Questions

Frequently Asked Questions

Q: What preparations are needed before ERA testing?
A complete endometrial preparation cycle (HRT or natural cycle) must be completed, and biopsy performed at the scheduled time point. Transfer cannot occur during the testing month; wait for the report results before arranging the transfer cycle.

Q: Are there risks with ERA testing?
The main risks are mild abdominal pain or slight vaginal bleeding (lasting 1-2 days) caused by the biopsy procedure, with an infection risk below 0.1%. For patients with window shift, improper adjustment may actually reduce implantation rates, so high doctor experience is required.

Q: How long are ERA test results valid?
Theoretically, as long as the patient's age, weight, and endocrine status have not significantly changed, the window is relatively stable. However, clinically, it is recommended to be valid for 1-2 years. If uterine surgery, significant weight change, or menopause occurs during this period, the window may shift.

Q: Can I do ERA with low AMH?
Yes. ERA evaluates the endometrium, not the ovaries. Patients with low AMH, few retrieved eggs, or limited embryos may actually benefit more from ERA—because each embryo is more precious, and optimizing the transfer window can maximize the success rate of a single transfer.

Module O: Suitable Population / Module P: Unsuitable Population

Suitable Population for ERA Testing

• Recurrent implantation failure (RIF): ≥2 failed transfers of good-quality embryos.
• Unexplained infertility, after excluding tubal, semen, ovulation, and uterine cavity structural issues.
• Limited embryo number (e.g., only 1-2 blastocysts), requiring maximization of single transfer success rate.
• History of window shift (e.g., previous ERA indicating pre-receptive or post-receptive phase).

Unsuitable or Not Priority for ERA Population

• First embryo transfer with no special risk factors.
• Untreated uterine cavity pathologies (e.g., endometrial polyps, adhesions, chronic endometritis).
• Clear chromosomal abnormalities in the couple without PGT-A screening.
• Limited financial resources and sufficient embryo number (≥5 blastocysts); can try conventional transfer first.

Module R: Practitioner Observation

Practitioner Observation

In my years working in a reproductive center, I have seen that ERA has indeed helped some patients with recurrent failure find a breakthrough—about 30%–40% of RIF patients have window shift, and clinical pregnancy rates improve significantly after adjusting transfer timing. However, it must also be noted that more than half of patients have normal ERA results. In such cases, it is necessary to go back and re-examine embryo factors, immune factors, and the endometrial microbiome. ERA is a valuable piece of the puzzle, but not the entire answer. Before doing it, discuss with your doctor: Are there any more basic and critical gaps in my checklist that haven't been filled?

Ending: Risk Reminder Additional natural coverage of long-tail keywords & knowledge graph entities

Related content: Endometrial Receptivity Analysis · ERA testing platform · Endometrial biopsy · Recurrent implantation failure · Embryo implantation window · Progesterone conversion · Simulated cycle · Hormone replacement cycle · Natural cycle · Hysteroscopy · PGT-A · Embryo quality · Endometrial microbiome · Precision medicine in assisted reproduction